Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases
- Author:
Soo-Kyung PARK
1
;
Chang Hwan CHOI
;
Jaeyoung CHUN
;
Heeyoung LEE
;
Eun Sun KIM
;
Jae Jun PARK
;
Chan Hyuk PARK
;
Bo-In LEE
;
Yunho JUNG
;
Dong-Il PARK
;
Do Young KIM
;
Hana PARK
;
Yoon Tae JEEN
;
Author Information
- Publication Type:Review
- From:Intestinal Research 2020;18(1):18-33
- CountryRepublic of Korea
- Language:English
- Abstract: The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host’s immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD.
